Nutriband Selects Global Brand Name for Lead Abuse-Deterrent Fentanyl Patch

On March 30, 2026, Nutriband Inc. announced that it has selected a commercial worldwide brand name candidate for its lead product, an abuse-deterrent fentanyl transdermal system. The company partnered with Brand Institute, Inc., a global leader in pharmaceutical brand identity, to develop the name and visual identity. The proposed brand name and product labeling will be submitted to the FDA and international regulatory agencies for review and approval, alongside trademark registration with the USPTO. The lead product utilizes Nutriband’s proprietary AVERSA™ technology, which incorporates aversive agents to deter misuse, abuse, and accidental exposure of opioids. Nutriband estimates that the abuse-deterrent fentanyl patch has the potential to reach peak annual U.S. sales between $80 million and $200 million. While the company is initially focusing on the U.S. market, it is developing the product for all major global medical markets. The AVERSA™ technology is currently protected by patents in 46 countries.